Alosetron (Lotronex) is back: Should I use it to treat my patients with irritable bowel syndrome?

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 1, 2003, Pages 64-65

  Shen, Bo ^a   Soffer, Edy E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT; TEGASEROD;

ABDOMINAL PAIN; CLINICAL FEATURE; CONSTIPATION; DAILY LIFE ACTIVITY; DEATH; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; FECES INCONTINENCE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMED CONSENT; IRRITABLE COLON; ISCHEMIC COLITIS; LIFESTYLE; NOTE; PATIENT CARE; PATIENT EDUCATION; PHYSICAL DISABILITY; PRESCRIPTION; REGISTER; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 0037241668     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.1.64     Document Type: Note

References (4)

1. Humphrey PPA, Bountra C, Clayton N, Kozlowski K. The therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1999; 13(suppl 2):31-38.
2. Mangel AW, Northcutt AR. The safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13(suppl 2):77-82.
3. Camilleri M, Northcutt AR, Kong S, Dukes G, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000; 355:1035-1040.
4. Shen B, Soffer EE. The challenge of irritable bowel syndrome: creating an alliance between patient and physician. Cleve Clin J Med 2001; 68:224-234.